Key information

🔎 Fund Overview

Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second product candidate VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a regulator of cholesterol and triglyceride metabolism.